Importance of competing risks in the analysis of anti-epileptic drug failure

Table 1 Classification of reasons for treatment change in 15 monotherapy trials

Trial	Still on drug at end of follow-up (censored)	Reason for withdrawal
		Adverse events	Seizure control	Remission	Seizure control and adverse events	Unclear	Total number of patients in trial
Heller et al., 1995¹⁸	131	25	29	36	15	7	243
De Silva et al., 1996¹⁹	41	9	35	59	19	4	167
Mattson et al., 1985²⁰	312	25	16	0	108	14	475
Mattson et al., 1992²¹	291	68	50	0	0	71	480
Richens et al., 1994²²	196	37	34	0	2	23	292
Verity et al., 1995²³	175	23	30	0	11	7	246
Brodie et al., 1995a²⁴	85	40	3	0	2	6	136
Brodie et al., 1995b²⁴	90	28	4	0	0	2	124
Ramsay et al., 1992²⁵	112	10	3	0	0	11	136
Turnbull et al., 1985²⁶	97	5	20	0	0	18	140
Placencia et al., 1993²⁷	159	10	0	0	0	23	192
Brodie et al., 1999²⁸	106	40	2	0	2	0	150
Bill et al., 1997²⁹	239	22	2	0	0	24	287
Guerreiro et al., 1997³⁰	158	16	7	0	1	11	193
Nieto-Barrera et al., 2001³¹	534	70	18	0	0	0	622

ISSN: 1745-6215